Evidence map›Paper›PMID 39548306›Full record

Trial reportBone marrow transplantation2025

Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.

Barbara Jeker, Laura Thalmann, Ulrike Bacher, Henning Nilius, Gaëlle Rhyner, Martin Sökler, Susanne Soltermann, Annette Winkler, Corinne Vorburger, Michael Daskalakis and 2 more

Abstract readClinical Trial, Phase IIRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Barbara Jeker *Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Laura Thalmann *Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Ulrike BacherDepartment of Hematology and Central Hematology Laboratory, University Hospital and University of Bern, Bern, Switzerland.
Henning NiliusDepartment of Clinical Chemistry, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Gaëlle RhynerDepartment of Medical Oncology, Cantonal Hospital Fribourg, Fribourg, Switzerland.
Martin SöklerDepartment of Medical Oncology and Hematology, Regional Hospital Thun, Thun, Switzerland.
Susanne SoltermannDepartment of Medical Oncology and Hematology, Bürgerspital Solothurn, Solothurn, Switzerland.
Annette WinklerDepartment of Medical Oncology and Hematology, Regional Hospital Biel, Biel, Switzerland.
Corinne VorburgerDepartment of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Michael DaskalakisDepartment of Hematology and Central Hematology Laboratory, University Hospital and University of Bern, Bern, Switzerland.ORCID 0000-0002-8138-0505
Michèle HoffmannDepartment of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland.
Thomas PabstDepartment of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland. Thomas.pabst@insel.ch.ORCID 0000-0002-6055-5257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In fit patients with newly diagnosed myeloma, high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is considered standard of care. For mobilization of CD34+ cells for ASCT, combined cytotoxic chemotherapy and G-CSF is commonly used. However, the importance of cytostatic chemotherapy for reliable mobilization remains unclear. This prospective randomized phase II non-inferiority trial compared G-GSF only (G) compared to standard chemotherapy/G-CSF (CG) for CD34+ mobilization. The primary endpoint was a less than 15% difference in successful stem cell collection ( ≥ 5.0 × 10

Indexed as

CytokinesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationMultiple MyelomaAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedProspective StudiesCytokinesGranulocyte Colony-Stimulating Factor

Identifiers

PMID39548306
PMCPMC11893443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.